Given the variability in biomarker cutoffs and the potential for misclassification, particularly in African Americans, our findings underscore the need to account for comorbidities such as blood-brain barrier dysfunction, which may influence CSF tau levels and impact both AD diagnostics and the assessment of tau-targeting therapies in clinical trials. Here, MAPT is linked to Alzheimer disease.